Chronic Fatigue Syndrome / ME (Investigational)
Investigational adjunct for myalgic encephalomyelitis/chronic fatigue syndrome; no RCT support; conventional pacing and symptom management remain primary.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for chronic fatigue syndrome (ME/CFS). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for ME/CFS is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based management of ME/CFS per IOM/NAM criteria and CDC guidance: pacing and energy management, treatment of comorbidities (orthostatic intolerance with fluid/salt/compression, sleep disorders, mood symptoms), avoiding graded exercise therapy in those with post-exertional malaise (NICE 2021 reversed prior recommendation), and symptom-targeted pharmacotherapy. Low-dose naltrexone and antiviral trials in selected cases.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Trigger of post-exertional malaise lasting days to weeks from procedure stress
- Worsening of fatigue, brain fog, or orthostatic symptoms
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Risk of vasovagal episode in patients with autonomic dysfunction
- Delay of pacing, energy management, and comorbidity treatment
- Risk of missed underlying treatable cause (thyroid, sleep apnea, anemia, depression)
- Quién no debería considerar esto
- Patients without thorough workup for treatable causes (thyroid, anemia, sleep apnea, depression, B12, Lyme, etc.)
- Patients with severe ME/CFS who are bed-bound (procedure-induced PEM risk too high)
- Patients with orthostatic intolerance, POTS, or severe autonomic dysfunction
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients
- Patients who have not engaged with pacing and energy management
- Qué preguntar a su clínico
- Have I been worked up for treatable causes (thyroid, sleep apnea, anemia, depression, B12, Lyme)?
- Has my orthostatic intolerance been managed (fluid, salt, compression, sometimes midodrine or fludrocortisone)?
- Have I learned pacing and energy management to avoid post-exertional malaise?
- Am I a candidate for low-dose naltrexone trial?
- Are my comorbidities (sleep, mood, pain) being addressed?
- What evidence specifically supports leech therapy for ME/CFS?
- What is the realistic risk of triggering post-exertional malaise from the procedure?
- Cuándo buscar atención urgente
- Severe new symptoms after the procedure that do not resolve in days
- Sudden palpitations, severe dizziness, or syncope (worsening orthostatic intolerance)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
- New chest pain, shortness of breath, or signs of cardiac event
Qué NO significa esto
- This is NOT FDA-cleared for chronic fatigue syndrome or ME/CFS.
- Anecdotal reports do NOT establish efficacy versus pacing, energy management, or comorbidity treatment.
- It does NOT replace workup for treatable causes (thyroid, sleep apnea, anemia, depression).
- It does NOT substitute for evidence-based ME/CFS management per IOM/NAM criteria and CDC guidance.
- It does NOT mean the procedure is risk-free — post-exertional malaise can be triggered by any stressor including a clinical procedure.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- neurological
- ICD-10
- G93.32, R53.82
- Safety tier
- medium
Evidence Summary
ME/CFS diagnosis follows IOM 2015 criteria (post-exertional malaise, unrefreshing sleep, cognitive impairment or orthostatic intolerance). Management remains supportive: pacing (avoiding post-exertional crashes), addressing comorbid orthostatic intolerance and sleep disorders, and limited symptom-directed pharmacotherapy. No controlled clinical trial of leech therapy for ME/CFS has been published; use is investigational and mechanistic only, and the neuroimmunologic pathophysiology of ME/CFS is poorly understood and not addressed by leech salivary pharmacology. Graded exercise therapy is no longer recommended due to post-exertional malaise risk; similar caution applies to any intervention requiring repeated sessions.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Michalsen A et al. (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Severe post-exertional malaise (treatment sessions may worsen)
- Orthostatic intolerance / POTS (risk of syncope)
- Mast cell activation syndrome
- Co-occurring fibromyalgia with allodynia at treatment sites
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.